{
    "nctId": "NCT02743637",
    "briefTitle": "A Dose Escalation Study of SDX-7320 in Patients With Advanced Refractory or Late-Stage Solid Tumors",
    "officialTitle": "A Phase 1 Dose Escalation Study of SDX-7320 to Assess the Safety and Tolerability in Patients With Advanced Refractory or Late-Stage Solid Tumors",
    "overallStatus": "COMPLETED",
    "conditions": "Advanced Malignancy, Advanced Solid Tumors, Neoplasm, Metastasis",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 32,
    "primaryOutcomeMeasure": "Number of participants with adverse events as a measure of safety and tolerability of SDX-7320 to find the recommended Phase II dose",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients have at least one site of radiographically measurable disease.\n* Eastern Cooperative Oncology Group (ECOG) status \u22641.\n* Adequate renal and liver functions.\n* Life expectancy \u22653 months.\n\nExclusion Criteria:\n\n* Patients that have undergone organ transplant surgery.\n* The patient has a known history of Hepatitis A, B, or C and is on active anti-viral therapy.\n* History of gastric bypass surgery or banding procedure.\n* Uncontrolled or refractory hypertension: systolic \\>180 or diastolic \\>110, or hypotension: systolic \\<90 or diastolic \\<50 despite medical treatment.\n* Participation in any other trial of an investigational agent within 30 days prior to first dose of study drug.\n* The resting 12-lead electrocardiogram obtained during screening shows QTc (Fridericia correction) \u2265470 ms or has a congenital prolonged QT syndrome.",
    "sex": "ALL",
    "minimumAge": "21 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}